Page reviewed Aug 23, 2026 · from FDA-approved labeling (Drugs@FDA) — no drug-specific Medicare LCD
Quick answer
Medicare benefit
Part B (physician-administered)
FDA-indicated diagnoses
9 ICD-10 codes
Governing policy
FDA indications (no LCD)
Contractor (MAC)
Per medical necessity
Source
FDA labeling
Page reviewed
Aug 23, 2026
HCPCS codes covered:
J0490
J0490
No drug-specific Medicare coverage article exists for Benlysta. Coverage is decided per medical necessity by your MAC. The FDA-approved indications below are the labeled uses Medicare generally pays for; an off-label use may be covered if supported by an approved compendium. Find your MAC by state →
What Medicare pays for Benlysta (2026 Q4)
2026 Q4 payment limit per billing unit for Benlysta’s HCPCS code (how ASP + 6% works):
| HCPCS | Description | Per unit | Allowed (ASP + 6%) |
|---|---|---|---|
| J0490 | Belimumab injection | 10 mg | $58.333 |
CMS ASP Drug Pricing File, 2026 Q4. Benlysta patient out-of-pocket estimate →
Worked billing example for Benlysta
A concrete, paste-checkable example using J0490’s own billing-unit basis and vial sizes — not a hypothetical.
| Scenario | 700 mg maintenance dose — 10 mg/kg IV q4wk for a 70 kg reference patient |
| Dose administered | 700 mg |
| Billing unit basis | 1 unit = 10 mg |
| Billing units (dose ÷ unit basis, rounded up) | 70 units of J0490 |
| Vial combination drawn (min-waste plan) | 6 × 120 mg vials |
| Discarded (waste) | 20 mg |
| Wastage modifier (JW / JZ) | Bill the 70 administered units on one claim line (no wastage modifier), and the 2 discarded units on a separate line with JW. Do not add JZ — JW and JZ are never billed together for the same drug on the same date of service. JW vs JZ, with examples → |
| Medicare allowable (ASP + 6%, 2026 Q4) | 72 units × $58.333/unit = $4199.98 |
Allowable, not paid: sequestration and the covered diagnosis still apply.
Dose source: drugs/benlysta.html — FAQ: "a 700 mg dose (70 kg patient × 10 mg/kg) is billed as 70 units.". Different dose or drug? Compute your own dose → or estimate the full cost & patient out-of-pocket →.
Benlysta (HCPCS J0490) is paid under Part B only when the claim’s ICD-10 code is one the MAC accepts; otherwise expect a CO-50 denial. How Part B drug coverage is decided →
Covered ICD-10 diagnoses for Benlysta
The 9 FDA-approved indications for J0490, grouped by condition — filter to find a code.
Systemic Lupus Erythematosus — 6 diagnoses (applies to J0490)
Diseases of the musculoskeletal system & connective tissue (6)
| ICD-10 | Covered diagnosis |
|---|---|
| M32.10 | SLE, organ or system involvement unspecified |
| M32.11 | Endocarditis in SLE |
| M32.12 | Pericarditis in SLE |
| M32.13 | Lung involvement in SLE |
| M32.19 | Other organ or system involvement in SLE |
| M32.9 | SLE, unspecified |
Lupus Nephritis — 2 diagnoses (applies to J0490)
Diseases of the musculoskeletal system & connective tissue (2)
| ICD-10 | Covered diagnosis |
|---|---|
| M32.14 | Glomerular disease in SLE |
| M32.15 | Tubulo-interstitial nephropathy in SLE |
SLE — 1 diagnoses (applies to J0490)
Diseases of the musculoskeletal system & connective tissue (1)
| ICD-10 | Covered diagnosis |
|---|---|
| M32.8 | Other forms of systemic lupus erythematosus |
What commercial payers require for Benlysta
Medicare Part B is only half the answer — most Benlysta claims are adjudicated by a commercial plan with its own medical policy. Below is what 26 commercial payers publish for Benlysta, read from each payer's own policy document. 25 of 25 that state a position require prior authorization (1 do not say clearly, so confirm those on the call), and 14 run a site-of-care program that can push the infusion out of the hospital outpatient setting.
| Payer | Prior auth | Preferred product first | Site of care | Indications named | Policy date |
|---|---|---|---|---|---|
| Aetna policy ↗ | Required | — | True; Utilization Management Policy on Site of Care for Specialty Drug Infusions applies | 1 | 2026-06-10 |
| Anthem / Elevance policy ↗ | Required | — | — | 2 | 2022-08-19 |
| Arkansas BCBS policy ↗ | Required | — | Site-of-care program applies | 2 | 2026-08-19 |
| BCBS Federal Employee Program policy ↗ | Required | — | — | 2 | 2025-10-01 |
| BCBS Kansas policy ↗ | Required | — | Site-of-care program applies | 2 | — |
| BCBS Louisiana policy ↗ | Required | — | — | 2 | 2025-08-01 |
| BCBS Michigan policy ↗ | Required | — | Site-of-care program applies | 2 | 2026-06-11 |
| BCBS Minnesota policy ↗ | Required | — | — | 2 | 2025-04-07 |
| BCBS Mississippi policy ↗ | Required | — | — | 2 | — |
| BCBS Nebraska policy ↗ | Required | — | — | 2 | 2025-11-05 |
| BCBS South Carolina policy ↗ | Required | — | Site-of-care program applies | 2 | — |
| BCBS Tennessee policy ↗ | Required | — | — | 2 | 2025-09-30 |
| Blue Shield of California policy ↗ | Required | — | preferred site of service required for certain plans; home, physician office, or independent infusion center not associated with a hospital | 2 | 2026-05-01 |
| Capital BlueCross policy ↗ | Required | — | — | 2 | — |
| CareFirst BCBS policy ↗ | Required | — | outpatient hospital | 1 | — |
| Centene / Ambetter policy ↗ | Required | — | — | 1 | — |
| Cigna policy ↗ | Required | — | Site-of-care program applies | 2 | 2026-06-01 |
| Excellus BCBS policy ↗ | Required | — | Site-of-care program applies | 2 | 2026-07-01 |
| Florida Blue policy ↗ | Required | — | — | 1 | 2026-07-01 |
| HCSC (IL/TX/OK/NM/MT) policy ↗ | Required | — | BCBS lists Benlysta (J0490) for Infusion Site of Care review: the payer reviews the medical need for the drug AND the place of infusion. Confirm the infusion site is approved with the prior authorization. | 2 | 2026-05-01 |
| Highmark BCBS policy ↗ | Required | — | administered in a physician’s office not affiliated with a hospital, specialized infusion centers not affiliated with a hospital or in the home | 2 | 2024-08-26 |
| HMSA (BCBS Hawaii) policy ↗ | Required | — | — | 2 | 2026-04-01 |
| Horizon BCBS NJ policy ↗ | Required | — | Refer to separate policy on Site of Administration for Infusion and Injectable Prescription Medications; Policy #142 | 1 | 2020-09-11 |
| Independence Blue Cross policy ↗ | Not stated — confirm on the call | — | — | 2 | 2022-10-24 |
| Premera Blue Cross policy ↗ | Required | — | Benlysta (belimumab) IV is subject to review for site of service administration. | 1 | 2026-07-02 |
| UnitedHealthcare policy ↗ | Required | — | Benlysta is on UnitedHealthcare's Provider Administered Drugs – Site of Care list (updated 10/01/2026). An infusion in a hospital outpatient department (place of service 19 or 22) has to meet that policy's criteria; a physician office, home infusion or ambulatory infusion suite is an accepted alternative. | 2 | 2025-12-01 |
What Benlysta payers put in writing
Quoted from the medical policies linked above — 28 distinct requirements across 26 payers. These are the sentences an appeal has to answer.
Clinical prerequisites — what must be true before they pay
Prescribed by or in consultation with a rheumatologist
— BCBS Kansas, BCBS South Carolina and 3 other payers policy ↗Member is using Benlysta in combination with other biologics.
— Aetna, BCBS Tennessee, HMSA (BCBS Hawaii) policy ↗Trial and failure, contraindication, or intolerance to two standard of care treatments for active SLE (e.g., antimalarials [e.g., Plaquenil (hydroxychloroquine)], corticosteroids [e.g., prednisone], or immunosuppressants [e.g., methotrexate, Imuran (azathioprine)])
— BCBS Kansas, BCBS South Carolina, Capital BlueCross policy ↗Autoantibody positive (i.e., anti-nuclear antibody [ANA] titer greater than or equal to 1:80 or anti-dsDNA level greater than or equal to 30 IU/mL)
— BCBS Kansas, BCBS South Carolina, Capital BlueCross policy ↗For Benlysta IV, patient is 5 years of age or older
— BCBS Kansas, BCBS South Carolina, Capital BlueCross policy ↗Patient is ≥ 5 years of age
— BCBS Louisiana, Cigna policy ↗
Prior authorization
The use of Benlysta is MEDICALLY NECESSARY for systemic lupus erythematosus when the following criteria has been met
— BCBS Kansas, BCBS South Carolina, Capital BlueCross policy ↗Effective October 1, 2021, Prior Approval is required for Belimumab.
— Arkansas BCBS policy ↗Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Benlysta
— BCBS Federal Employee Program policy ↗J0490 Infusion Site of Care, Provider Administered Drug Therapy Injection Belimumab 10 Mg
— HCSC (IL/TX/OK/NM/MT) policy ↗The use of Benlysta is MEDICALLY NECESSARY for active lupus nephritis when the following criteria has been met
— BCBS Kansas policy ↗Coverage eligibility for the use of belimumab (Benlysta) will be considered when ALL of the following patient selection criteria are met
— BCBS Louisiana policy ↗
Quantity and frequency limits
Quantity Limits: Align with FDA recommended dosing
— BCBS Michigan policy ↗The prescribed dosage is within the program quantity limits based on FDA approved labeled dosage.
— BCBS Mississippi policy ↗Initial: 10mg/kg every 2 weeks for 3 doses Maintenance: 10mg/kg every 4 weeks
— BCBS Tennessee policy ↗Commercial – 6 months or to member’s renewal date, whichever is longer
— Centene / Ambetter policy ↗
Dosing rules
Benlysta (belimumab) 120 mg, 400 mg vial for intravenous (IV) infusion* 10 mg/kg every 4 weeks
— Anthem / Elevance policy ↗The IV form is dosed at 10 mg/kg at 2 week intervals for the first 3 doses and at 4 week intervals thereafter.
— BCBS Kansas policy ↗Dose of Benlysta intravenous (IV) does not exceed 10 mg/kg at 2-week intervals for the first 3 doses followed by 10mg/kg at 4-week intervals thereafter
— BCBS Louisiana policy ↗Administer 10 mg/kg intravenously every 4 weeks
— BCBS Minnesota policy ↗(Benlysta) Effective: 05/01/2026 Page 3 of 4 Not to exceed 10 mg/kg given intravenously on
— Blue Shield of California policy ↗20 response at Week 24 was 28% with Benlysta 10 mg/kg).5 Numerous other agents
— Cigna policy ↗
Reauthorization / continuation
Renewal Criteria: Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit
— BCBS Michigan policy ↗
Site-of-care restrictions
Site of Care Utilization Management Policy applies to belimumab (Benlysta).
— Aetna policy ↗Reason for prior authorization where medical necessity review is required for both therapy and place of infusion (Infusion Site of Care)
— HCSC (IL/TX/OK/NM/MT) policy ↗The drugs listed below require prior authorization AND may only be authorized to be administered in certain locations (sites of care), such as an infusion center or the patient’s home. Note that the site-of-care requirement does not apply if the drug is being used for cancer treatment.
— BCBS South Carolina policy ↗Please refer to a separate policy on Site of Administration for Infusion and Injectable Prescription Medications (Policy #142)
— Horizon BCBS NJ policy ↗Benlysta (belimumab) IV is subject to review for site of service administration.
— Premera Blue Cross policy ↗
Read from each payer's published medical policy between 2026-08-03 and 2026-08-13. Every requirement above is quoted from the policy it links to. Commercial policy changes without notice — confirm before you bill.
How to bill Benlysta
Put a medically necessary, FDA-indicated diagnosis from the list above on the claim line with J0490. Matching codes, units and JZ/JW wastage →
Which policy governs Benlysta
No drug-specific LCD or Article — see the note at the top of this page. Find your MAC → What an LCD, an Article and an NCD each govern →
If a claim for Benlysta is denied
With no drug-specific Article, the usual cause is a diagnosis the MAC does not accept as medically necessary for J0490, or an off-label use with no compendium support. The five denial patterns and how to fix each →
Frequently asked questions
- Is Benlysta covered by Medicare?
- It depends on how it is given. All 8 Medicare Administrative Contractors list Benlysta (J0490) as route-dependent on their self-administered drug lists: the form given in the office by a clinician is covered under Part B when medically necessary, and the self-injected form is excluded from Part B.
- What diagnoses are covered for Benlysta (J0490)?
- Medicare publishes no drug-specific covered-diagnosis list for J0490. The 9 ICD-10 codes here are the FDA-approved indications; an off-label use needs approved-compendium support (DrugDex, NCCN) to be payable.
- Which Medicare policy covers Benlysta?
- Each Medicare Administrative Contractor's self-administered drug (SAD) exclusion article decides whether Part B pays: part b depends on the route (8 of 8 macs). No drug-specific LCD or Billing & Coding Article exists for Benlysta.
- Why was my Benlysta claim denied as not medically necessary?
- The most common cause is a diagnosis the MAC doesn't consider medically necessary for J0490. Bill a covered/FDA-approved indication from the list below, document medical necessity, and confirm any local guidance with your MAC.
Related references
Covered is only half the answer.
You know the diagnosis is payable. Now quote the patient before the visit and catch underpayments: get Benlysta's exact Medicare allowed amount, your payer's rate vs. ASP+6%, and the patient's out-of-pocket — in about 30 seconds, free.
Estimate Benlysta cost & patient owe →Source & verification
- Source
- FDA-approved indications (Drugs@FDA labeling) mapped to ICD-10-CM. No drug-specific Medicare LCD/Article exists for Benlysta — Part B coverage is determined per medical necessity by your MAC.
- Primary sources
- DailyMed — Benlysta prescribing information · CMS Part B Drug ASP Pricing File — the quarterly payment limit quoted above · CMS Medicare Coverage Database — searched for “Benlysta”; no drug-specific NCD, LCD or Billing & Coding Article exists, which is why the FDA-indicated codes above are the working list
- Page last reviewed by CareCost
- Aug 23, 2026 (coverage data retrieved 2026-09-21; we re-verify against CMS quarterly).
- Notes
- ICD-10-CM is public domain; CPT® (AMA) is intentionally not listed. Reference, not billing advice — built from the CMS Coverage API per our methodology; corrections to editorial@carecostestimate.com.